Novavax, Inc. (NASDAQ:NVAX - Get Free Report) Director James F. Young sold 7,500 shares of Novavax stock in a transaction on Friday, June 21st. The stock was sold at an average price of $14.09, for a total value of $105,675.00. Following the sale, the director now directly owns 61,760 shares of the company's stock, valued at $870,198.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Novavax Price Performance
NASDAQ NVAX opened at $14.00 on Wednesday. The business has a 50 day simple moving average of $11.44 and a 200 day simple moving average of $7.06. Novavax, Inc. has a 52-week low of $3.53 and a 52-week high of $23.86.
Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by ($0.01). The firm had revenue of $93.90 million for the quarter, compared to the consensus estimate of $71.32 million. During the same period last year, the company earned ($3.41) earnings per share. The firm's quarterly revenue was up 15.9% compared to the same quarter last year. Equities analysts expect that Novavax, Inc. will post 0.49 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Trump’s arrest is phase one
From Porter & Company | Ad
When I said Obama would seek a third term…
They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible.
But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.”
Please, watch this now before it’s too late.
NVAX has been the subject of several analyst reports. HC Wainwright restated a "buy" rating and set a $19.00 target price on shares of Novavax in a research report on Monday, May 13th. Bank of America boosted their price objective on shares of Novavax from $12.00 to $18.00 and gave the company a "neutral" rating in a report on Friday, June 14th. B. Riley increased their target price on shares of Novavax from $11.00 to $29.00 and gave the stock a "buy" rating in a report on Thursday, May 23rd. JPMorgan Chase & Co. raised shares of Novavax from an "underweight" rating to a "neutral" rating in a report on Friday, May 10th. Finally, TD Cowen upped their price objective on shares of Novavax from $5.00 to $10.00 and gave the company a "hold" rating in a research report on Monday, May 13th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $19.00.
Read Our Latest Analysis on Novavax
Institutional Trading of Novavax
Several hedge funds and other institutional investors have recently modified their holdings of the company. Coatue Management LLC acquired a new position in shares of Novavax during the fourth quarter worth about $7,294,000. Shah Capital Management lifted its stake in Novavax by 22.9% in the 4th quarter. Shah Capital Management now owns 7,780,756 shares of the biopharmaceutical company's stock valued at $37,348,000 after acquiring an additional 1,450,000 shares in the last quarter. Farallon Capital Management LLC acquired a new position in Novavax during the 1st quarter worth approximately $5,406,000. Vanguard Group Inc. grew its stake in shares of Novavax by 9.3% during the 3rd quarter. Vanguard Group Inc. now owns 11,551,476 shares of the biopharmaceutical company's stock worth $83,633,000 after acquiring an additional 978,873 shares in the last quarter. Finally, Rafferty Asset Management LLC raised its holdings in shares of Novavax by 62.4% in the fourth quarter. Rafferty Asset Management LLC now owns 1,611,840 shares of the biopharmaceutical company's stock valued at $7,737,000 after purchasing an additional 619,370 shares during the last quarter. Institutional investors and hedge funds own 53.04% of the company's stock.
Novavax Company Profile
(
Get Free Report)
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
